Alzamend Neuro Partners With Massachusetts General Hospital For A Phase II Clinical Trial Of AL001, A Next‑Generation Lithium Therapeutic Drug Candidate

Author: Benzinga Newsdesk | August 12, 2024 08:18am

• Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study
• Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted; the goal is to compare lithium in human brain and brain structures to identify a potentially ideal dose of AL001 that is safe and effective as current products

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it is partnering with Massachusetts General Hospital as its contract research organization ("CRO") to conduct first of its kind Phase II clinical study of AL001 for treatment of patients with MDD. Massachusetts General Hospital is the original and largest clinical education and research facility of Harvard Medical School/Harvard University and houses the world's largest hospital-based research program.

Posted In: ALZN